A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
== Cultivation == Angelica is hardy to 5 °C (41 °F) and can be cultivated at elevations of 1,500 to 3,000 metres (5,000–10,000 ft). Seedlings need to be kept out of direct sunlight, but the mature plant can withstand it. Angelica requires deep moist fertile soil and is perennial if prevented from going to seed.
== Modern therapeutic research == Tetrodotoxin has been investigated as a possible treatment for cancer-associated pain. Early clinical trials demonstrate significant pain relief in some patients. It has also been studied in relation to migraine headaches. Mutations in one particular TTX-sensitive Na+ channel are associated with some migraine headaches, although it is unclear as to whether this has any therapeutic relevance for most people with migraine. Tetrodotoxin has been used clinically to relieve negative affects associated with heroin withdrawal.
=== Reduction === Like esters, most carboxylic acids can be reduced to alcohols by hydrogenation, or using hydride transferring agents such as lithium aluminium hydride. Strong alkyl transferring agents, such as organolithium compounds but not Grignard reagents, will reduce carboxylic acids to ketones along with transfer of the alkyl group. The Vilsmaier reagent (N,N-Dimethyl(chloromethylene)ammonium chloride; [ClHC=N+(CH3)2]Cl−) is a highly chemoselective agent for carboxylic acid reduction. It selectively activates the carboxylic acid to give the carboxymethyleneammonium salt, which can be reduced by a mild reductant like lithium tris(t-butoxy)aluminum hydride to afford an aldehyde in a one pot procedure. This procedure is known to tolerate reactive carbonyl functionalities such as ketone as well as moderately reactive ester, olefin, nitrile, and halide moieties.
Sources: en.wikipedia.org
Polling before the election indicated profound dissatisfaction with the state of American democracy. According to an October 25 ABC/Ipsos poll, 49% of Americans saw Trump as a fascist, described as "a political extremist who seeks to act as a dictator, disregards individual rights and threatens or uses force against their opponents". Meanwhile, only 22% saw Harris as a fascist by this definition. Some Republicans were concerned that Trump's former impeachment and four criminal indictments were attempts to influence the election and keep him from office; however, there is no evidence that Trump's criminal trials were "election interference" orchestrated by Biden and the Democratic Party, and Trump also continued to repeat false claims that the 2020 election was "rigged" and stolen from him. Trump's 2024 presidential campaign was criticized by legal experts, historians, and political scientists for making increasingly dehumanizing, violent, and authoritarian statements. Trump's platform called for the vast expansion of presidential powers and the executive branch over every part of the federal government. Trump called for stripping employment protections for thousands of career civil service employees (a provision known as Schedule F appointment that had been adopted by Trump at the end of 2020) and replacing them with political loyalists if deemed an "obstacle to his agenda" within federal agencies, the United States Intelligence Community, State Department, and Department of Defense.
=== EC 1.17.98 With other, known, physiological acceptors === EC 1.17.98.1: bile-acid 7α-dehydroxylase. Now known to be catalyzed by multiple enzymes. EC 1.17.98.2: bacteriochlorophyllide c C-71-hydroxylase EC 1.17.98.3: formate dehydrogenase (coenzyme F420) EC 1.17.98.4: formate dehydrogenase (hydrogenase)
Swelling around the tumor Difficulty in moving the extremity that has the tumor, including a limp. Soreness localized to the area of the tumor or in the extremity. Neurological symptoms. Pain or discomfort: numbness, burning, or "pins and needles". Dizziness and/or loss of balance.
(ARP) publishers of the bodybuilding magazine Muscular Development and several other magazines. David Blechman retired in 1996, and passed the title of CEO to his son Ross, while the other sons were installed as corporate officers. He died on July 7, 2000. In 2001 Twinlab sold ARP to Steve Blechman who then resigned from Twinlab. After slumping sales in 2002, the company filed a voluntary petition for Chapter 11 reorganization with the U.S. Bankruptcy Court for the Southern District of New York in September 2003. In 2004, Twinlab Corp., Twin Laboratories Inc. and Twin Laboratories (UK) Ltd. were purchased for $65 million by IdeaSphere Inc. Ideasphere also known as ISI brands, and which also operated as Twinlab, went on to acquire other dietary supplement brands such as Metabolife, Nature's Herbs, Alvita Teas, and a publisher, Rebus LLC. In January 2014 Twinlab's CEO Tom Tolworthy announced that he would partner with Capstone Financial Group to raise $130M to conduct a management buyout of Twinlab and make other acquisitions, via an entity called Twinlab Consolidation Corporation. The transaction was completed in August 2014. In July 2018, Anthony Zolezzi, founder of Bubba Gump Shrimp Company and Pet Promise Natural Dog Food was named CEO of Twinlab, after being appointed to the Board of Directors the previous May.
Sources: en.wikipedia.org
== Prognosis == As of 2012, the five-year survival rate for systemic scleroderma was about 85%, whereas the 10-year survival rate was just under 70%. This varies according to the subtype; while localized scleroderma rarely results in death, the systemic form can, and the diffuse systemic form carries a worse prognosis than the limited form. The major scleroderma-related causes of death are: pulmonary hypertension, pulmonary fibrosis, and scleroderma renal crisis. People with scleroderma are also at a heightened risk for developing osteoporosis and for contracting cancer (especially liver, lung, haematologic, and bladder cancers). Scleroderma is also associated with an increased risk of cardiovascular disease. According to a study of an Australian cohort, between 1985 and 2015, the average life expectancy of a person with scleroderma increased from 66 years to 74 years (the average Australian life expectancy increased from 76 to 82 years in the same period).
Primary percutaneous coronary intervention (PCI) is the treatment of choice for STEMI if it can be performed in a timely manner, ideally within 90–120 minutes of contact with a medical provider. Some recommend it is also done in NSTEMI within 1–3 days, particularly when considered high-risk. A 2017 review, however, did not find a difference between early versus later PCI in NSTEMI. PCI involves small probes, inserted through peripheral blood vessels such as the femoral artery or radial artery into the blood vessels of the heart. The probes are then used to identify and clear blockages using small balloons, which are dragged through the blocked segment, dragging away the clot, or the insertion of stents. Coronary artery bypass grafting is only considered when the affected area of heart muscle is large, and PCI is unsuitable, for example with difficult cardiac anatomy. After PCI, people are generally placed on aspirin indefinitely and on dual antiplatelet therapy (generally aspirin and clopidogrel) for at least a year.
== Career == Macor began his industrial career at Pfizer in 1986, where he was a co-inventor of eletriptan, a triptan marketed as Relpax for the acute treatment of migraine. Eletriptan was approved by the FDA in 2002. He later joined Bristol-Myers Squibb in 1997, where he served as executive director of neuroscience chemistry. At Bristol-Myers Squibb, he was a co-inventor in the program that produced the CGRP receptor antagonists rimegepant and zavegepant, which were subsequently developed by Biohaven Pharmaceuticals and approved by the FDA in 2020 and 2023, respectively, for the treatment of migraine. He is also a co-inventor of sparsentan, a dual endothelin and angiotensin II receptor antagonist developed by Travere Therapeutics and approved by the FDA in 2023 for the reduction of proteinuria in adults with IgA nephropathy. Macor’s work at Bristol-Myers Squibb also included the company’s Alzheimer’s disease program, where he contributed to the discovery of avagacestat (BMS-708163), a γ-secretase inhibitor that advanced to Phase 2 clinical trials before development was discontinued. Macor is an author on more than 220 peer-reviewed publications and a named inventor on 150 issued U.S. patents.
==== Axon injury ==== For severe nerve entrapment, nerve axons can be injured to the point of destruction. Axon injury is also known as axonmetesis or a Sunderland type 2 nerve injury where the endoneurial tubes are preserved. If an axon is injured, the axonal transport system may not function. Since the axon depends on its connection to the cell body, the disrupted axonal transport will cause segmental death of the axon distal to the injury site in a process called Wallerian degeneration. This will result in a complete conduction block, leading to muscle weakness (motor nerve) or numbness (sensory nerve). Provided that the endoneurial tube is not disrupted, there is still a pathway for the axon at the injury site to regrow, but the growth is very slow (approximately 1mm/day). Recovery can take months and is often partial.
Marsha Linehan's biosocial developmental theory posits that BPD arises from the interaction between a child's inherent emotional vulnerability and an invalidating environment—an environment characterized by the neglect, ridicule, dismissal, or discouragement of a child's emotions and needs. Due to it drawing on attachment theory, which centers Western nuclear family norms, the diagnosis of BPD has been critiqued by Indigenous and decolonial scholars for possibly pathologizing Indigenous and collectivist cultural forms of caregiving.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.